Swiss skincare company Galderma boosts 2025 sales forecast, shares surge

Galderma Raises 2025 Outlook Amid Sales Growth

ZURICH (Reuters) – Swiss skincare company Galderma increased its 2025 outlook after a 12.2% net sales growth in the first half of the year, with strong performance in the U.S. and international markets.

The company now anticipates net sales growth of 12% to 14% for the year at constant currency, up from a previous estimate of 10-12%. It maintains a core EBITDA margin guidance of around 23%.

Galderma’s shares, which began trading on the Swiss stock exchange in March 2024, have surged by over 140%, with an additional 8% jump after the latest market opening.

CEO Flemming Ornskov highlighted robust growth in dermatological skincare, injectable aesthetics, and therapeutic dermatology, noting the U.S.’s crucial role, accounting for over 40% of sales.

From Miami, where Galderma is establishing its new U.S. headquarters, Ornskov emphasized the importance of building infrastructure and manufacturing capabilities in the U.S.

The company views the impact of U.S. tariffs as manageable and is prepared to handle further tariff effects and shifts in consumer demand.

(Reporting by Dave Graham, Editing by Rachel More)